Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLX-787-ODT for Fasciculations in ALS
NCT03338114Phase 2Withdrawn
- Sponsor
- Salarius Pharmaceuticals
- Start
- Nov 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of FLX-787 in amyotrophic lateral sclerosis (ALS), fasciculation, sponsored by Salarius Pharmaceuticals. Planned start Nov 2017; status: withdrawn.
02
Drugs
FLX-787
03
Conditions
amyotrophic lateral sclerosis (ALS)fasciculation
Beyond the preview
Go deeper on NCT03338114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03338114.